Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models 

Consistent with Xilio’s clinically-validated masking technology, XTX601 was well tolerated in non-human primates with a favorable therapeutic index